Pharmion shareholders to decide Celgene merger on March 6

By Lisa Kerner

Charlotte, N.C., Feb. 19 - Pharmion Corp. will hold a special meeting of stockholders on March 6.

Stockholders will be asked to consider the approval and adoption of the merger agreement among Pharmion, Celgene Corp. and Cobalt Acquisition LLC.

As previously reported, Celgene agreed to acquire Pharmion for $72 per share in a cash and stock transaction valued at $2.9 billion.

Pharmion is an oncology company based in Boulder, Colo.

Celgene is a Summit, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.